BridgeBio Pharma Inc
NASDAQ:BBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BridgeBio Pharma Inc
NASDAQ:BBIO
|
US |
|
J
|
Jindal Poly Investment and Finance Company Ltd
BSE:536773
|
IN |
|
Matsumoto Yushi-Seiyaku Co Ltd
TSE:4365
|
JP |
|
GLP J-REIT
TSE:3281
|
JP |
|
Futaba Corp
TSE:6986
|
JP |
|
T
|
Taiwan Chelic Co Ltd
TWSE:4555
|
TW |
|
J
|
JSL Construction & Development Co Ltd
TWSE:2540
|
TW |
|
D
|
Dr Reddy's Laboratories Ltd
BSE:500124
|
IN |
|
A
|
Alam Maritim Resources Bhd
KLSE:ALAM
|
MY |
|
V
|
Valora Holding AG
SIX:VALN
|
CH |
|
F
|
First International Bank of Israel Ltd
TASE:FIBI
|
IL |
|
Alpha Teknova Inc
NASDAQ:TKNO
|
US |
|
G
|
Genfit SA
PAR:GNFT
|
FR |
Wall Street
Price Targets
BBIO Price Targets Summary
BridgeBio Pharma Inc
According to Wall Street analysts, the average 1-year price target for
BBIO
is 99.16 USD
with a low forecast of 68.11 USD and a high forecast of 164.85 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BBIO's stock price target?
Price Target
99.16
USD
According to Wall Street analysts, the average 1-year price target for
BBIO
is 99.16 USD
with a low forecast of 68.11 USD and a high forecast of 164.85 USD.
What is BridgeBio Pharma Inc's Revenue forecast?
Projected CAGR
69%
The
compound annual growth rate
of
BridgeBio Pharma Inc's revenue for the next 3 years is
69%.